^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DM005

    i
    Other names: DM005, YH013
    Company:
    Biocytogen, Doma Pharma
    Drug class:
    Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate, c-MET-targeted antibody-drug conjugate
    Related drugs:
    1year
    YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy (AACR 2023)
    Moreover, in multiple patient-derived xenografts of NSCLC and pancreatic ductal adenocarcinoma (PDAC), which co-express EGFR and MET, YH013 demonstrated superior and durable efficacy that outperformed benchmark antibodies at a lower dose (3 mg/kg). Collectively, these results suggest that YH013 can be an effective treatment option for EGFR and MET co-expressing tumors and overcome MET-driven EGFR-TKI resistance to improve patient outcomes.
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • EGFR expression • MET expression • EGFR H1975 • EGFR expression + MET expression
    |
    DM005